Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to
respond to the combination of fulvestrant and abemaciclib, and this approach may represent an
effective therapeutic strategy to manage such patients.